Deals & Corporate Governance

  • September 18, 2026

    Lilly Left Nektar Drug 'Damaged Goods,' Jury Told At Trial End

    Eli Lilly & Co. turned Nektar Therapeutics' autoimmune-disease drug Rezpeg into "damaged goods" by breaching the companies' co-development deal and delaying the medication's development in favor of a competing drug the pharma giant subsequently acquired, Nektar's counsel told a California federal jury during closing arguments Friday in the $1 billion case.

  • September 18, 2026

    Cooley-Led Electra Therapeutics Prices Upsized $350M IPO

    Cooley LLP-advised Electra Therapeutics, a venture-backed biotech firm developing antibodies for immune diseases and cancer, began trading Friday after raising $350 million in an upsized IPO.

  • September 16, 2026

    Muscular Dystrophy Drug Co. Beats Investor Suit Over Risks

    A Massachusetts federal judge denied investors another chance to rework their suit accusing Sarepta Therapeutics and its executives of misleading the market about the safety and efficacy of their muscular dystrophy treatments, saying it fails to show they knew about issues with the products and trials when they made certain statements.

  • September 15, 2026

    Pharma Mulls Drug Launch Delays Amid 'Most Favored' Prices

    The Trump administration's efforts to lower U.S. drug prices is pushing some companies to consider pausing drug launches abroad.

  • September 15, 2026

    Express Scripts Accused Of Shorting Independent Pharmacies

    A dozen independent Arkansas pharmacies on Tuesday hauled Express Scripts into Missouri state court, accusing the pharmacy benefit management giant of continuously shorting them on prescription reimbursements despite Arkansas' efforts to combat underpayments.

  • September 15, 2026

    Insurers Can't Nix $195M Opioid Coverage Bid, Trustee Says

    Chubb, Liberty Mutual and Lloyd's of London units and other insurers can't get off the hook for covering the remainder of third-party payor opioid lawsuits against Endo International, a representative for a trust of the bankrupt pharmaceutical company told a Pennsylvania federal court.

  • September 15, 2026

    Molina Escapes Investor Action Over Guidance Cuts, For Now

    Health insurance provider Molina Healthcare and two of its executives have, for now, escaped a shareholder suit accusing them of misleading investors about medical costs and internal controls before the company repeatedly slashed its 2025 earnings guidance, with a California federal judge finding that none of the suit's challenged statements are actionable.

  • September 15, 2026

    Cooley, Latham Prep Electra Therapeutics' $325M IPO Plan

    Biotechnology firm Electra Therapeutics plans to make its public debut this week through an estimated $325 million initial public offering steered by Cooley LLP and Latham & Watkins LLP.

  • September 14, 2026

    NC Residents Lose Class Cert. Bid In Hospital Antitrust Fight

    A state court judge has denied class certification to a group of residents in western North Carolina in their healthcare antitrust case, saying they fell short of showing classwide impact in the form of allegedly increased premiums and decreased quality of care.

  • September 11, 2026

    Fed. Circ. Agrees Globus Didn't Infringe Spinal Surgery IP

    The Federal Circuit on Friday upheld a Pennsylvania federal judge's decisions clearing Globus Medical Inc. of infringing Moskowitz Family LLC spinal surgery tool patents, agreeing that language used in the patents' opening statement, or preamble, limited their scope.

  • September 10, 2026

    Biosimilars Boast Big Savings But Face IP Risks, Report Says

    There are no biosimilar drugs in development for 90% of biologic products set to lose their patent exclusivity by 2034, according to a report released Thursday by the Association for Accessible Medicines, which warned that current patent policy threatens generic-drug development. 

  • September 09, 2026

    FTC Chucks Biden-Era Health App Breach Notification Policy

    The Federal Trade Commission, as part of its regulatory streamlining, has rescinded a Biden-era policy requiring health applications and smart devices that collect information to warn users when their medical data has been breached.

  • September 08, 2026

    MFN Pricing Could Upend Drugmakers' Cross-Border Deals

    A new program rolled out by the Trump administration that aims to decrease prescription drug prices in the U.S. has been causing consternation among drug companies, which fear the resulting pricing uncertainty could gut licensing deals that were inked long before the program was even on the horizon.

  • September 08, 2026

    Biogen Must Face Pharmacies' MS Drug Monopoly Suit

    An Illinois federal judge on Tuesday refused to dismiss Walgreens and Kroger's lawsuit accusing Biogen Inc. of illegally stifling competition for its multiple sclerosis drug Tecfidera, saying they've made sufficient allegations at this point in the case to suggest they've "suffered a concrete injury as a result of Biogen's conduct."

  • September 03, 2026

    American Healthcare REIT Buys $696M East Coast Portfolio

    American Healthcare REIT said it has acquired eight Class A senior housing communities on the East Coast for a combined $696 million.

  • September 02, 2026

    American Healthcare Buys $572M Senior Housing Portfolio

    American Healthcare REIT Inc. has paid $572 million to Kensington Senior Living for six luxury senior housing communities that have 464 units in total, the clinical healthcare-focused real estate investment trust announced.

  • September 02, 2026

    REIT Pays $200M For 4-Site Minn. Senior Housing Portfolio

    Senior housing and healthcare-focused real estate investment trust LTC Properties said Wednesday that it has acquired four senior housing properties in Minnesota for $200 million.

  • August 31, 2026

    9 More Drug Cos. Make Pricing Agreements With US

    Nine more branded drug manufacturers reached deals cutting prices on their medications, President Donald Trump announced Monday, with nearly 90% of such products now being covered by "most-favored nation" deals in the United States.

  • August 28, 2026

    Doctor Shorted Practice Co-Owner On Distributions, Suit Says

    A Colorado ophthalmologist failed to pay the co-owner of his practice the full distribution amounts owed to that physician while overpaying himself, according to a lawsuit filed in state court.

  • August 27, 2026

    Guardant Suits Against Tempus AI Clear Dismissal Bids

    A Delaware federal judge has refused to throw out litigation accusing Tempus AI Inc. of infringing Guardant Health Inc. patents covering technology used to analyze cancer-related genetic data and help guide testing and treatment.

  • August 27, 2026

    GAO Says CMS Should Rethink $52M Task Order

    The Centers for Medicare and Medicaid Services applied unstated evaluation criteria when passing on a company's $49 million offer to provide support services for a health care facility surveyor training program in favor of a more expensive bid, according to a decision by the U.S. Government Accountability Office. 

  • August 27, 2026

    Mich. Hospitals Defend CVS 340B Drug Savings Suit

    University of Michigan Hospitals and Health Centers urged a Michigan federal judge Wednesday to preserve its suit claiming that CVS Health Corp. diverted millions of dollars earmarked for indigent healthcare to itself, saying the conduct clearly amounts to a racketeering scheme.

  • August 26, 2026

    Bankrupt Villages Health System Agrees To $541.5M FCA Deal

    Florida-based The Villages Health System has agreed to shell out more than $541.5 million to resolve allegations it violated the False Claims Act by submitting false diagnosis codes to get more money from Medicare, conduct that it disclosed itself, the U.S. Department of Justice said Wednesday.

  • August 25, 2026

    Hospitals Lean On Payors Amid ACA, Medicaid Cuts

    Hospitals feeling a mounting financial squeeze are getting more aggressive in contract negotiations and reimbursement disputes with insurance companies.

  • August 25, 2026

    23andMe, Calif. Spar Over Data Claims In Bankruptcy Court

    The bankruptcy trust for DNA testing company 23andMe and the state of California locked horns Tuesday over the debtor's plan to trim the size of claims that the state has asserted over a data breach in 2023.

Expert Analysis

  • Risk Reduction Lessons For PE Firms From PowerSchool Suit

    Author Photo

    A California federal court's recent orders allowing claims against Bain Capital to proceed based on a data breach at its subsidiary PowerSchool indicate that private equity firms need to strategically approach acquisition activities to avoid cybersecurity risks, say attorneys at Womble Bond.

  • PowerSchool Data Breach Ruling Underscores PE Liability

    Author Photo

    The recent California federal court decision in PowerSchool, where Bain Capital was unable to dismiss claims relating to a data breach based in part on Bain's preinvestment activities, is an important addition to the line of cases addressing investor liability for acts of a portfolio company, says Mark Kelley at MoloLamken.

  • Calif. Case Raises Questions For Medical Practice Investors

    Author Photo

    The California attorney general's amicus brief in Art Center v. WCE and the California Medical Association's response highlight how the California appeals court's ruling could significantly affect the structure and enforceability of succession arrangements in medical practice ownership, say attorneys at Ropes & Gray.

  • How CMS Fraud Priorities Complicate Provider Acquisitions

    Author Photo

    As the Centers for Medicare & Medicaid Services steps up usage of its affiliates authority and post-transaction audits, parties contemplating the acquisition or sale of home health and hospice providers should take steps to avoid the potential suspension of Medicare billing privileges, say attorneys at Alston & Bird.

  • The Challenge Of Stabilizing Rural Hospitals On The Brink

    Author Photo

    The outlook for rural hospitals has grown more concerning, as recent policy and regulatory developments are decreasing hospital revenues and increasing the cost of uncompensated care, which may result in additional hospital closures, service reductions, or mergers and acquisitions, say Omur Celmanbet, Kristy Piccinini and Sabiha Quddus at FTI Consulting.

  • Bid Protest Spotlight: Evidence, Tailored Talks, Materiality

    Author Photo

    In this month's bid protest roundup, Brian Doll at MoFo delves into three recent decisions from the Government Accountability Office about the evidentiary standards necessary to sustain a protest, discussions tailored to individual proposals, and misrepresentation claims involving factors irrelevant to the agency's decision.

  • Senior Housing Demands A Distinct Dealmaking Playbook

    Author Photo

    An aging population and evolving state regulations underscore a critical reality that senior housing assets can undergo operational or compliance shifts during dealmaking, highlighting the need for unique contractual safeguards like expanded disclosures, anchored notice obligations, and targeted closing conditions and remedies, say attorneys at Goodwin.

  • OhioHealth Suit Signals Higher Antitrust Heat On Hospitals

    Author Photo

    The recent antitrust lawsuit against OhioHealth by the U.S. Justice Department and Ohio attorney general shows that federal and state enforcers are closely examining the competition issues in the healthcare sector, including restrictive contracts and antisteering practices, say attorneys at Freshfields.

  • What Changed For Healthcare Transaction Law In 2025

    Author Photo

    Though much of the legislation introduced last year to expand state scrutiny of healthcare transactions did not pass, investors should pay close attention to the overarching trends, which are likely to continue in this year's legislative sessions, say attorneys at Ropes & Gray.

  • Key Trends In Healthcare Antitrust In 2025

    Author Photo

    The healthcare industry braced for significant antitrust enforcement shifts last year driven by a change in administration, and understanding the implications of these trends is critical for healthcare organizations' risk management and strategic decision-making in the year ahead, say attorneys at Michael Best.

  • The 5 Most Important Bid Protest Decisions Of 2025

    Author Photo

    In a shifting bid protest landscape, five decisions in 2025 from the Federal Circuit, the U.S. Court of Federal Claims and the U.S. Government Accountability Office that addressed bedrock questions about jurisdictional reach and the breadth of agency discretion are likely to have a lasting impact, say attorneys at Bradley Arant.

  • Top 5 Antitrust Issues For In-House Counsel To Watch In 2026

    Author Photo

    With Trump administration enforcement policy having largely taken shape last year, antitrust issues that in-house counsel should have on the radar range from scrutiny of technology-assisted pricing to the return of merger remedies, say attorneys at Squire Patton.

  • Nonprofits Face Uncertainty Over Political Activity Rules

    Author Photo

    Two federal court decisions suggesting that the Internal Revenue Service's rules for 501(c)(4) organizations' political activity may be too vague to survive constitutional scrutiny leave nonprofit organizations caught between constitutional limits on government regulation of speech and tax limits on their exempt status, say attorneys at BakerHostetler.